A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Erin Schenk, MD, PhD
Study ID
Protocol Number: 20-2584
More information available at ClinicalTrials.gov: NCT02922764
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers